title: Impact of Helicobacter pylori eradication on circulating adiponectin in humans.
abstract: BACKGROUND
  The relationship between Helicobacter pylori infection and metabolic syndrome is not well understood. Adiponectin is an adipose-derived protein considered to play a significant role in the development of metabolic syndrome. The aim of this study was to clarify the influence of H. pylori infection on circulating adiponectin in humans.
  
  
  METHODS
  In a prospective study, 456 patients underwent endoscopy and H. pylori testing. All of the 338 H. pylori -positive patients received eradication therapy. Treatment was successful in 241 patients. Circulating adiponectin and other metabolic parameters were measured at baseline in all patients and 12 weeks after eradication therapy in those initially positive for H. pylori.
  
  
  RESULTS
  Circulating adiponectin levels were not different between H. pylori -positive and H. pylori -negative patients. In the group with successful eradication, levels of total adiponectin and each multimer form were significantly increased after therapy. Conversely, the levels of total adiponectin and high-molecular-weight adiponectin, but not middle-molecular-weight and low-molecular-weight adiponectin, were increased in the group with unsuccessful eradication after the therapy.
  
  
  CONCLUSIONS
  Eradication therapy of H. pylori increased circulating adiponectin levels in Japanese individuals and could be beneficial for preventing metabolic syndrome conditions.
authors.affiliation: Department of Gastroenterology, Social Insurance Kyoto Hospital, Koyamashimofusa-cho 27, Kita-ku, Kyoto, 603-8151, Japan. t-ando@yellow.plala.or.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Ando
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Takagi
authors.forename: Eiko
authors.initials: E
authors.lastname: Imamoto
authors.forename: Etsuko
authors.initials: E
authors.lastname: Kishimoto
authors.forename: Akira
authors.initials: A
authors.lastname: Okajima
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Uchiyama
authors.forename: Osamu
authors.initials: O
authors.lastname: Handa
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Yagi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kokura
authors.forename: Yuji
authors.initials: Y
authors.lastname: Naito
authors.forename: Shigeto
authors.initials: S
authors.lastname: Mizuno
authors.forename: Akihiro
authors.initials: A
authors.lastname: Asakawa
authors.forename: Akio
authors.initials: A
authors.lastname: Inui
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Yoshikawa
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001944:Breath Tests; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000150:complications* / Q000175:diagnosis; D008875:Middle Aged; D011446:Prospective Studies; D013577:Syndrome; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D052242:Adiponectin; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents